"Genistein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An isoflavonoid derived from soy products. It inhibits PROTEIN-TYROSINE KINASE and topoisomerase-II (DNA TOPOISOMERASES, TYPE II); activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 PHASE arrest in human and murine cell lines and inhibits PROTEIN-TYROSINE KINASE.
| Descriptor ID |
D019833
|
| MeSH Number(s) |
D03.383.663.283.266.450.400.375 D03.633.100.150.266.450.400.375
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Genistein".
Below are MeSH descriptors whose meaning is more specific than "Genistein".
This graph shows the total number of publications written about "Genistein" by people in this website by year, and whether "Genistein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 2 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 2 | 3 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 3 | 5 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 1 | 3 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genistein" by people in Profiles.
-
Rashid R, Kumari A, Chattopadhyay N, Jha R, Rajender S. Genistein lowers fertility with pronounced effect in males: Meta-analyses on pre-clinical studies. Andrologia. 2022 Oct; 54(9):e14511.
-
Schneider LS, Hernandez G, Zhao L, Franke AA, Chen YL, Pawluczyk S, Mack WJ, Brinton RD. Safety and feasibility of estrogen receptor-? targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial. Menopause. 2019 08; 26(8):874-884.
-
George A, Raji I, Cinar B, Kucuk O, Oyelere AK. Design, synthesis, and evaluation of the antiproliferative activity of hydantoin-derived antiandrogen-genistein conjugates. Bioorg Med Chem. 2018 05 01; 26(8):1481-1487.
-
Hernandez G, Zhao L, Franke AA, Chen YL, Mack WJ, Brinton RD, Schneider LS. Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor ?-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women. Menopause. 2018 02; 25(2):191-196.
-
Zarmouh NO, Eyunni SK, Soliman KF. The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor. BMC Complement Altern Med. 2017 Jan 10; 17(1):34.
-
Zhao Q, Zhao M, Parris AB, Xing Y, Yang X. Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells. Int J Oncol. 2016 Sep; 49(3):1203-10.
-
Romagnolo DF, Daniels KD, Grunwald JT, Ramos SA, Propper CR, Selmin OI. Epigenetics of breast cancer: Modifying role of environmental and bioactive food compounds. Mol Nutr Food Res. 2016 06; 60(6):1310-29.
-
de la Parra C, Castillo-Pichardo L, Cruz-Collazo A, Cubano L, Redis R, Calin GA, Dharmawardhane S. Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of Genistein. Nutr Cancer. 2016; 68(1):154-64.
-
Ding M, Franke AA, Rosner BA, Giovannucci E, van Dam RM, Tworoger SS, Hu FB, Sun Q. Urinary isoflavonoids and risk of type 2 diabetes: a prospective investigation in US women. Br J Nutr. 2015 Nov 28; 114(10):1694-701.
-
Xiong P, Wang R, Zhang X, DeLa Torre E, Leon F, Zhang Q, Zheng S, Wang G, Chen QH. Design, Synthesis, and Evaluation of Genistein Analogues as Anti-Cancer Agents. Anticancer Agents Med Chem. 2015; 15(9):1197-203.